Previous 10 | Next 10 |
home / stock / mrk / mrk articles
Merck (NYSE: MRK) announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP...
On Thursday, the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) unanimou...
Merck (NYSE: MRK) and its partner Daiichi Sankyo announced that the FDA has issued a complete response letter ("CRL") to the biologics li...
Oppenheimer initiated coverage on Keros Therapeutics Inc (NASDAQ:KROS), a clinical-stage biopharmaceutical company that develops and commercializes...
Oppenheimer initiated coverage on Gossamer Bio Inc (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, with an Outperform rating and a price...
Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary event...
Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. B...
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and...
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its ...
News, Short Squeeze, Breakout and More Instantly...
How one employee's upbringing and career journey have motivated her to fight inequities around the world NORTHAMPTON, MA / ACCESSWIRE / July 16, 2024 / For Priya Agrawal, health equity has been a lifelong concern and a guiding principle in the work she's done across industries. As a young...
Symposia will highlight work to overcome HIV-related stigma and discuss the evolving state of HIV treatment and prevention Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced upcoming data presentations and programming at the 25 th International ...
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret™, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration, as well as preclinical candidates Merck (NYSE: MRK), known as MSD outside of t...